Companies Investors People

Drop to look up

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing
Alternatives

For iPhone and iPad

Resources

Documentation
Use Cases
CLI
MCP
Sitemap

aVenture is an AI-native agentic deep research tool for researching and finding companies and people, and is a high-quality alternative to AlphaSense, CB Insights, Crunchbase, Dealroom, Harmonic, Owler, Perplexity Finance, PitchBook, Preqin, PrivCo, Synaptic, and Tracxn.

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Terms of service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Ansun Biopharma›

Library

Ansun Biopharma

Ansun BioPharma, a San Diego-based clinical stage biopharmaceutical company, develops host-directed anti-viral therapies.

: 27
: Company
: 2002
: San Diego, CA, USUnited States

Library

ansunbiopharma.comCrawled Oct 14, 2026

Topics

Publication type

Search the library

Content origin

Row density

Press

1 page

News/news
The publication describes research on DAS181, an investigational antiviral drug that inhibited replication of zoonotic influenza A virus subtype H7N9 and protected mice from lethality.

Careers & Hiring

4 pages

Career Opportunities/careers/career-opportunities
Careers/careers
Ansun offers career opportunities in a science-driven environment and invites interested applicants to submit a CV with the relevant job code to careers@ansunbiopharma.com.
Our Benefits/careers/our-benefits
Our Company, People & Culture/careers/our-company-people-culture

Team

2 pages

Board of Directors/about/board-of-directors
Scientific Advisory Board/about/scientific-advisory-board

About

2 pages

About/about
Ansun develops therapeutics for viral diseases using its expertise in sialic acid biology. Its team has drug discovery, development and commercialization expertise and aims to develop products to save lives, especially for vulnerable and underserved populations.
Who We Are/about/who-we-are
Ansun is a team of approximately 25 scientists, doctors and visionaries based in San Diego, California. Its mission is to save the lives of the most vulnerable.

Contact

1 page

Contact/contact
San Diego 11568 Sorrento Valley Road San Diego, CA 92121 USA Get In Touch

Homepage

1 page

Homepage/
ANSwer to Unmet Needs Ansun Biopharma is leading the effort to combat severe viral infections that have no existing treatment options Ongoing Clinical Trials ANSwer to Unmet Needs Ansun Biopharma is leading the